These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 31139690)

  • 1. Treatment of natalizumab-associated PML with filgrastim.
    Stefoski D; Balabanov R; Waheed R; Ko M; Koralnik IJ; Sierra Morales F
    Ann Clin Transl Neurol; 2019 May; 6(5):923-931. PubMed ID: 31139690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is maraviroc useful in multiple sclerosis patients with natalizumab-related progressive multifocal leukoencephalopathy?
    Scarpazza C; Prosperini L; Mancinelli CR; De Rossi N; Lugaresi A; Capobianco M; Moiola L; Naldi P; Imberti L; Gerevini S; Capra R
    J Neurol Sci; 2017 Jul; 378():233-237. PubMed ID: 28566170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.
    Wijburg MT; Kleerekooper I; Lissenberg-Witte BI; de Vos M; Warnke C; Uitdehaag BMJ; Barkhof F; Killestein J; Wattjes MP
    JAMA Neurol; 2018 Jul; 75(7):827-833. PubMed ID: 29532061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies.
    Ho PR; Koendgen H; Campbell N; Haddock B; Richman S; Chang I
    Lancet Neurol; 2017 Nov; 16(11):925-933. PubMed ID: 28969984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.
    Clifford DB; De Luca A; Simpson DM; Arendt G; Giovannoni G; Nath A
    Lancet Neurol; 2010 Apr; 9(4):438-46. PubMed ID: 20298967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance of PML diagnostic criteria in natalizumab-associated PML: data from the Dutch-Belgian cohort.
    Wijburg MT; Warnke C; Barkhof F; Uitdehaag BMJ; Killestein J; Wattjes MP
    J Neurol Neurosurg Psychiatry; 2019 Jan; 90(1):44-46. PubMed ID: 30100552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atypical Multiple Sclerosis Lesions or Progressive Multifocal Leukoencephalopathy Lesions: That Is the Question.
    De Mercanti SF; Gned D; Matta M; Iudicello M; Franchin E; Clerico M
    J Investig Med High Impact Case Rep; 2020; 8():2324709620939802. PubMed ID: 32646245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful pregnancy after natalizumab-associated progressive multifocal leukoencephalopathy in a patient with multiple sclerosis.
    Pitarokoili K; Hellwig K; Lukas C; Gold R
    Mult Scler; 2017 Mar; 23(3):483-486. PubMed ID: 28260421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Punctate pattern: A promising imaging marker for the diagnosis of natalizumab-associated PML.
    Hodel J; Darchis C; Outteryck O; Verclytte S; Deramecourt V; Lacour A; Zins M; Pruvo JP; Vermersch P; Leclerc X
    Neurology; 2016 Apr; 86(16):1516-23. PubMed ID: 27009257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Presentation and Outcome in S1P-RM and Natalizumab-Associated Progressive Multifocal Leukoencephalopathy: A Multicenter Cohort Study.
    Blant JC; De Rossi NN; Gold R; Maurousset A; Kraemer M; Romero-Pinel L; Misu T; Ouallet JC; Pallix Guyot M; Gerevini S; Bakirtzis C; Piñar Morales R; Vlad B; Karypidis P; Moisset X; Derfuss TJ; Jelcic I; Martin-Blondel G; Ayzenberg I; McGraw C; Laplaud DA; Du Pasquier RA; Bernard-Valnet R;
    Neurol Neuroimmunol Neuroinflamm; 2024 Sep; 11(5):e200281. PubMed ID: 38991170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progressive multifocal leukoencephalopathy in two natalizumab-treated stepsisters: An intriguing coincidence.
    Bacchetta F; Mathias A; Schluep M; Du Pasquier R
    Mult Scler; 2017 Feb; 23(2):300-303. PubMed ID: 28165319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Refractory epilepsy following natalizumab associated PML.
    Abkur TM; Kearney H; Hennessy MJ
    Mult Scler Relat Disord; 2018 Feb; 20():1-2. PubMed ID: 29253743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MRI characteristics of early PML-IRIS after natalizumab treatment in patients with MS.
    Wattjes MP; Wijburg MT; Vennegoor A; Witte BI; de Vos M; Richert ND; Uitdehaag BM; Barkhof F; Killestein J;
    J Neurol Neurosurg Psychiatry; 2016 Aug; 87(8):879-84. PubMed ID: 26369555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JC virus persistence following progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumab.
    Ryschkewitsch CF; Jensen PN; Monaco MC; Major EO
    Ann Neurol; 2010 Sep; 68(3):384-91. PubMed ID: 20818792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of plasma exchange on serum anti-JC virus antibodies.
    Subramanyam M; Plavina T; Khatri BO; Fox RJ; Goelz SE
    Mult Scler; 2013 Jun; 19(7):912-9. PubMed ID: 23232602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Course of neuropsychological impairment during natalizumab-associated progressive multifocal leukoencephalopathy.
    Kinner M; Prehn C; Schneider R; Schroeder C; Kolb E; Gold R; Hoepner R; Chan A
    Eur J Neurol; 2021 Mar; 28(3):921-927. PubMed ID: 33085811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring the John Cunningham virus throughout natalizumab treatment in multiple sclerosis patients.
    Domínguez-Mozo MI; García-Montojo M; Arias-Leal A; García-Martínez Á; Santiago JL; Casanova I; Galán V; Arroyo R; Fernández-Arquero M; Alvarez-Lafuente R
    Eur J Neurol; 2016 Jan; 23(1):182-9. PubMed ID: 26498276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent Registry.
    Prosperini L; de Rossi N; Scarpazza C; Moiola L; Cosottini M; Gerevini S; Capra R;
    PLoS One; 2016; 11(12):e0168376. PubMed ID: 27997580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients.
    Wattjes MP; Wijburg MT; Vennegoor A; Witte BI; Roosendaal SD; Sanchez E; Liu Y; Martins Jarnalo CO; Richert ND; Uitdehaag BM; Barkhof F; Killestein J
    Mult Scler; 2016 Aug; 22(9):1174-83. PubMed ID: 26564995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JCV GCN in a natalizumab-treated MS patient is associated with mutations of the VP1 capsid gene.
    Agnihotri SP; Dang X; Carter JL; Fife TD; Bord E; Batson S; Koralnik IJ
    Neurology; 2014 Aug; 83(8):727-32. PubMed ID: 25037207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.